key: cord-0902885-tlnd9z0o authors: Leuking, R.; Narasimhan, M.; Mahimainathan, L.; mut, A.; Liu, Y.; Xing, C.; Larsen, C.; Clark, A. E.; SoRelle, J. A. title: Delta/ Omicron and Omicron/BA.2 co-infections occurring in Immunocompromised hosts date: 2022-04-06 journal: nan DOI: 10.1101/2022.04.04.22273058 sha: 86018dd36fb80489b95eca0c762d49204d3112ac doc_id: 902885 cord_uid: tlnd9z0o Concomitant infection of multiple SARS-CoV-2 variants has become an increasing concern, as this scenario increases the likelihood of recombinant variants. Detecting co-infection of SARS-CoV-2 variants is difficult to detect by whole genome sequencing approaches, but genotyping methods facilitate detection. We describe 2 cases of Delta/Omicron and 2 cases of Omicron/ BA.2 co-infection as detected by a multiplex genotyping fragment analysis method. Findings were confirmed by whole genome sequencing. Review of the patient characteristics revealed co-morbidities and conditions which weaken the immune system and may make them more susceptible to harboring SARS-CoV-2 variant co-infections. Ongoing genomic surveillance has revealed the trajectory of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections largely coincide with the emergence of dominant genetic lineages (variants) harboring distinct genetic mutations. SARS-CoV-2 variants of concern (VOCs) have arisen, harboring a high number of mutations and increased infectivity, morbidity, immune evasion, and mortality among infected individuals. Evolutionarily, the SARS-CoV-2 virus mutates relatively slowly compared to HIV or influenza RNA viruses owing to the presence of nonstructural protein 14 (Nsp14) that harbors 3'-to-5' exoribonuclease (ExoN), a unique RNA proof-reader not found in other RNA viruses. Genome-wide association studies (GWAS) indeed indicate that mutations in error-correcting nsp14 protein exhibited a strongest association with increased SARS-CoV-2 genome-wide mutation load (1) (2) (3) . Other factors can also change the rate of evolution as VOCs rise to high frequencies. For instance, when multiple variants circulate, the possibility of genomic recombination between different strains or sub-lineages increases. Recombination potentially occurs when two distinct lineages are present in the same host. High levels of recombination may occur sporadically in RNA viruses and recombination may not be a trait optimized by natural selection. Importantly, these novel genotypes are concerning and may result in a more virulent virus in a short amount of time. Indeed, this was recently observed to occur when the Omicron variant out-competed the Delta VOC (4) . In addition, we have observed that severely immunocompromised (IC) hosts with no antibody immune response may harbor the virus for up to a year with no increased mutation rate. However, some IC hosts may exhibit an immune response low enough to prevent viral clearance, but that is high enough select for viral variation. Such a scenario has been observed in uncontrolled HIV patients with low but detectable CD4 counts or other transplant patients (5) (6) (7) . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.04.22273058 doi: medRxiv preprint While a combination of genetic drift, recombination, and population immunity could play a key role in the continual emergence of VOCs, reasons underlying this emergence remain poorly understood. In the face of population immunity, we and others have previously reported that in IC patients, viruses elude vaccines or remain more pathogenic (8) (9) (10) . Further, Sun et al. (11) have shown that IC individuals exhibit a higher risk of COVID-19 breakthrough infection. Of note, weakened immune system was determined to be a potential source for multiple amino acid substitutions and deletions in the spike protein, with increased resistance to neutralizing antibodies (5) . Thus, these studies suggest IC states prolong viral survival and provide opportunities for additional mutations. It is thus critical to address whether underlying immunodeficiency or immunosuppressive therapy impacts the emergence of recombinant variants by permitting co-infection of variants. Typically, molecular tools such as whole genome sequencing (WGS) have facilitated evolutionary and epidemiological monitoring of SARS-CoV-2 in near real-time and enabled us to better prepare and combat the threat. Detection and characterization of co-infection and emerging recombinant variants by current WGS methods is challenging with respect to obtaining and analyzing complete viral genomes from clinical samples in a timely and costeffective manner. However, genotyping methods allow sensitive detection of multiple mutations simultaneously, which can provide a clue to the existence of co-infection. Using fragment analysis genotyping method for detecting SARS-CoV-2 variants (12), we detected two cases of a Delta/Omicron co-infection and two cases of an BA.1/BA.2 co-infection. These findings were confirmed by WGS. The present manuscript presents two cases of SARS-CoV-2 Delta/Omicron (B.1.617.2/ B.1.1.529) co-infection, and the first two cases of co-infection with BA.1/BA.2 Omicron sublineages among IC patients. The knowledge of co-infections is critical and will enforce an . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.04.22273058 doi: medRxiv preprint evidence-based understanding of the mechanisms driving genomic variability, patterns of emergence, and the clinical management and treatment of COVID-19 cases with co-infection. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.04.22273058 doi: medRxiv preprint prophylaxis. With discontinued antibiotics and tapered steroids, the patient was discharged without supplemental oxygen and a FEV1 near baseline. During both infections, the patient had undetectable IgG and IgM antibodies against nucleocapsid (Figure 1 ), which is useful for distinguishing infection-associated immune response from vaccine-related response (13) . He was given monoclonal antibody therapy (casirivimab and imdevimab) during both infections, resulting in very high Spike IgG antibody levels. Notably, casirivimab and imdevimab are human monoclonal antibodies that bind to nonoverlapping epitopes of the S protein RBD of SARS-CoV-2 (anti-SARS-CoV-2 antibodies). The lack of nucleocapsid antibody response reflects an inability to mount an antibody response due to immunosuppression. Several studies have previously reported that patients with preexisting immunosuppressive conditions or those who undergo immunosuppressive treatments exhibit low or no ability to mount antibody response (8, 9) . Following the identification of the primary case reported in this work, we continued surveillance of all positive SARS-CoV-2 specimens for additional cases of SARS-CoV-2 coinfections with different VOCs. While we report the above case in the greatest level of clinical detail, we have also encountered another specimen from a female in her 70's with uncontrolled diabetes had Delta/Omicron coinfection (diagnosed 1st week of January 2022, had received 3 mRNA vaccinations). Only a single sample was available but returned the same results when re-extracted to rule out contamination. We next identified three independent patients with BA.1/ BA.2 co-infection (Table 1, collected last week of February and last week of March). One was a woman in her 60's with a hematologic malignancy after 5 rounds of chemotherapy and had no COVID-19 vaccinations. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Sequencing showed separate forward and reverse reads (colored red and blue respectively, Figure 3B ) for the BA.1mutations (S:69_70Del and A67V) and BA.2 (no mutations present) in the RDR1 region. In the RDR2 region, the BA.1 deletion (S:143_145Del) is present . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 2C ). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2022. As this is the first reported case report of BA.1/BA.2 variant co-infections so soon after an Omicron/Delta co-infection, we predict such co-infections will continue to occur when one variant takes over another. Specifically, this is likely to occur in IC hosts who have trouble clearing the virus, thus, allowing it to effectively adapt by exploiting the host cell conditions. In this context, host proteins, sirtuin 1 and 5 (SIRT1 and SIRT5) involved in energy, metabolism, and survival processes, have been recently shown to interact with SARS-CoV-2 Nsp14 and generating a lethal phenotype of SARS-CoV-2 with effective replication and/or long-term propagation (16). Importantly, the expression and activity of SIRT1 was shown to be enhanced by the steroid, prednisolone (17), which the case patient has been receiving since transplant at a dose of 7.5mg daily until the November COVID diagnosis and continued with 60 mg daily following this initial diagnosis. Thus, any such alterations in host cell pathways due to IC and/or IS drugs that can interfere with and dampen the SARS-CoV-2 nsp14-ExoN is likely to hamper the intrinsic fidelity and contribute to high-level mutagenesis. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.04.22273058 doi: medRxiv preprint The small number of cases observed prevents generalizable comments on whether coinfection protracts disease course or has more severe symptoms. The serological responses among IC patients are dampened as exemplified by the lack of Nucleocapsid IgG antibody response after months of primary and secondary infection in this lung transplant patient. The high anti-Spike IgG levels were due to monoclonal antibody use. The outcomes of these patients indicates unvaccinated and immunosuppressed patients are at higher risk for more severe disease. A key learning point of these cases is that protracted disease presents an opportunity for additional exposure or the emergence of new variants. Of note, it has been reported that persistently infected IC patients accumulate amino acid substitutions or deletions in different regions of human SARS-CoV-2 spike protein and thus are conceived to be a source of new immune-escape viral variants (5, 18, 19) . Also, CD4+ T-cell depletion (<20 CD4+ T-cell counts) as found in IC persons, including persons living with HIV/AIDS, has been determined to increase the risk of giving rise to SARS-CoV-2 resistance mutations (6-7). In contrast, an absent immune response does not reject virus and thus there is no competitive advantage for acquiring resistance mutations. Furthermore, we have learned that these cases of SARS-CoV-2 co-infection are most likely to occur in times when there is a diversity of variants in circulation. Thus, it is likely that co-infections will continue to occur and methods to monitor this should be considered. The most commonly used variant detection method is currently WGS. However, criteria for calling variants are that mutations must be detected at >50% or higher levels of variant allele frequencies. Additionally, due to biases introduced in amplicon-based library preparation, whole genome sequencing cannot accurately quantify differences in variant levels. This cut-off prevents minor allele-frequencies to be counted for detection of co-infections. Genotyping methods offer a sensitive alternative where multiple mutations can be detected at once provided . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.04.04.22273058 doi: medRxiv preprint a wild-type and mutant allele can be detected simultaneously. In this scenario, fragment analysis is superior, because it can detect multiple types of deletions simultaneously. This method of multiplex SARS-CoV-2 genotyping by fragment analysis lends itself to not only detecting concurrent variant mutational signatures but also allows relative quantitation of the genomic material present. This quantitation can be cross applied to the CT value to infer whether an infection is active or not. For our patient, a 25% decrease in Delta nucleic acid corresponds with a 4-fold difference (2 CT value difference), which indicates the Delta variant was still active and not shedding dead virus. Therefore, we conclude that SARS-CoV-2 co-infections will continue and represent a source of viral evolution, which in many cases can be effectively monitored using a fragment analysis genotyping approach. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted April 6, 2022. Mutations of SARS-CoV-2 nsp14 exhibit strong association with increased genome-wide mutation load Genomic diversity of SARS-CoV-2 can be accelerated by a mutation in the nsp14 gene. bioRxiv Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN Evidence for SARS-CoV-2 delta and omicron coinfections and recombination Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape SARS-CoV-2 Neutralization Resistance Mutations in Patient with HIV/AIDS Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv National COVID Cohort Collaborative (N3C) Consortium. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US Multiplex Fragment Analysis Identifies SARS-CoV-2 Variants Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays among infected, recovered, and vaccinated groups